The Full Wiki

Almorexant: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
(2R)-2-[(1S)- 6,7-dimethoxy- 1-{2-[4-(trifluoromethyl)phenyl]ethyl}- 3,4-dihydroisoquinolin-2(1H)-yl]- N-methyl- 2-phenylacetamide
CAS number 871224-64-5
ATC code none
PubChem 23727689
Chemical data
Formula C29H32ClF3N2O3 
Mol. mass 512.6 g/mol (free base)
SMILES eMolecules & PubChem
Pharmacokinetic data
Metabolism Hepatic
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes Oral

Almorexant (INN, codenamed ACT-078573) is a competitive receptor antagonist of the OX1 and OX2 orexin receptors, being developed by the pharmaceutical company Actelion for the treatment of primary insomnia. As of 2008, it is in Phase III clinical trials.[1]


Mechanism of action

Almorexant is a competitive, dual OX1 and OX2 receptor antagonist and selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.

Clinical uses

Almorexant currently is under development for clinical use in primary insomnia.

See also


  1. ^ Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1). (August 26, 2008). Retrieved on October 6, 2008.

External links



Got something to say? Make a comment.
Your name
Your email address